Immunostimulants drugs - for COVID-19   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 1.07 [0.73, 1.57]< 10%1 study (1/-)36.6 %highnot evaluable lowcrucial-
deaths 1.10 [0.93, 1.29]< 10%8 studies (8/-)12.7 %highserious lowcrucial-
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical improvement 1.16 [0.78, 1.74]> 152%4 studies (4/-)76.7 %highnot evaluable lowimportant-
clinical improvement (28-day) 1.42 [0.65, 3.10]> 10%1 study (1/-)81.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 3.41 [1.33, 8.73]> 10%1 study (1/-)99.5 %some concernnot evaluable moderateimportant-
clinical worsening 0.63 [0.08, 4.94]< 153%2 studies (2/-)67.1 %highnot evaluable lowimportant-
death or ventilation 0.83 [0.35, 1.93]< 146%2 studies (2/-)67.1 %highnot evaluable lowimportant-
hospital discharge 3.90 [0.90, 17.01]> 10%2 studies (2/-)96.5 %highnot evaluable lowimportant-
PCR-negative conversion 6.33 [1.54, 26.00]> 10%1 study (1/-)99.5 %NAnot evaluable important-
PCR-negative conversion (7-day) 1.20 [1.00, 1.44]> 10%1 study (1/-)97.4 %highnot evaluable lowimportant-
PCR-negative conversion (time to event analysis only) 3.26 [1.53, 6.95]> 10%1 study (1/-)99.9 %highnot evaluable lowimportant-
ventilation 0.29 [0.05, 1.56]< 10%1 study (1/-)92.5 %some concernnot evaluable moderateimportant-
ICU admission 0.13 [0.01, 1.46]< 176%2 studies (2/-)95.0 %some concernnot evaluable moderatenon important-

-- safety endpoints 00

serious adverse events 0.96 [0.29, 3.17]< 10%1 study (1/-)52.4 %some concernnot evaluable moderateimportant-
adverse events 1.33 [0.45, 3.92]< 10%1 study (1/-)30.1 %highnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 87,95,94,90,91,97 90, 95, 91